PSTI did a mistake "FDA’s Animal Rule regulatory pathway" a long pathway. co burnt $19m past 12 months. today's fluff pr say it all."look forward to discussing","pilot study was not powered to demonstrate statistical significance". more cash will be needed Although recent offering imo.it seems to me too expensive right now ($140m cap).
they have better products to focus on. CBLI Already Received Europe Orphan Drug Status For Acute Radiation Syndrome Treatment and already 150 healthy human subjects have demonstrated the safety. a strong Backup by Russian Federation Ministry of Industry. FDA agreement recently too.
$15.2m in cash, Solid balance sheet, reduced about $12m expenses in 2016.
all imo and maybe I'm wrong. days will tell.
News 
Market Data 
Discover 
